Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denis Maillet

Showing results (41-50 of 70) with videos related to

Pageof 7
Sort By:
European Urology Oncology|November 11, 2025
PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: Rationale, Mechanisms, and Clinical ApplicationsStéphane Oudard, Marc-Olivier Timsit, Denis Maillet, et al.
Cancer Treatment Reviews|October 10, 2018
Management of non-metastatic castrate-resistant prostate cancer: A systematic reviewYohann Loriot, Stéphane Supiot, Jean-Baptiste Beauval, et al.
Sante Publique (Vandoeuvre-Les-Nancy, France)|May 22, 2025
Pierre Yves Meunier, Karfala Maiga, Denis Maillet, et al.
World Journal of Urology|January 10, 2025
Efficacy of immune checkpoint inhibitors in renal cell carcinoma venous tumour thrombus shrinkage (UroCCR 128)Fabien Moinard-Butot, Jonathan Thouvenin, Pierre Bigot, et al.
Sante Publique (Vandoeuvre-Les-Nancy, France)|February 13, 2026
Pierre-Yves Meunier, Karfala Maiga, Denis Maillet, et al.
Cancers|September 9, 2022
Embryonated Chicken Tumor Xenografts Derived from Circulating Tumor Cells as a Relevant Model to Study Metastatic Dissemination: A Proof of ConceptXavier Rousset, Denis Maillet, Emmanuel Grolleau, et al.
Critical Reviews in Oncology/Hematology|February 21, 2018
Loco-regional treatment for castration-resistant prostate cancer: Is there any rationale? A critical review from the AFU-GETUGJean-Baptiste Beauval, Yohann Loriot, Christophe Hennequin, et al.
JCO Oncology Practice|July 22, 2024
Evolving Practices in Immune-Related Adverse Event Management: Insights From the IMMUCARE Multidisciplinary BoardRomain Varnier, Clara Fontaine-Delaruelle, Nathalie Freymond, et al.
Cancer Chemotherapy and Pharmacology|April 3, 2023
A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trialAlicja Puszkiel, Benoit You, Léa Payen, et al.
Cancers|April 12, 2022
Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective StudyZoé Guillaume, Emeline Colomba, Jonathan Thouvenin, et al.
Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
European Urology Oncology|November 11, 2025
PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: Rationale, Mechanisms, and Clinical ApplicationsStéphane Oudard, Marc-Olivier Timsit, Denis Maillet, et al.
Cancer Treatment Reviews|October 10, 2018
Management of non-metastatic castrate-resistant prostate cancer: A systematic reviewYohann Loriot, Stéphane Supiot, Jean-Baptiste Beauval, et al.
Sante Publique (Vandoeuvre-Les-Nancy, France)|May 22, 2025
Pierre Yves Meunier, Karfala Maiga, Denis Maillet, et al.
World Journal of Urology|January 10, 2025
Efficacy of immune checkpoint inhibitors in renal cell carcinoma venous tumour thrombus shrinkage (UroCCR 128)Fabien Moinard-Butot, Jonathan Thouvenin, Pierre Bigot, et al.
Sante Publique (Vandoeuvre-Les-Nancy, France)|February 13, 2026
Pierre-Yves Meunier, Karfala Maiga, Denis Maillet, et al.
Cancers|September 9, 2022
Embryonated Chicken Tumor Xenografts Derived from Circulating Tumor Cells as a Relevant Model to Study Metastatic Dissemination: A Proof of ConceptXavier Rousset, Denis Maillet, Emmanuel Grolleau, et al.
Critical Reviews in Oncology/Hematology|February 21, 2018
Loco-regional treatment for castration-resistant prostate cancer: Is there any rationale? A critical review from the AFU-GETUGJean-Baptiste Beauval, Yohann Loriot, Christophe Hennequin, et al.
JCO Oncology Practice|July 22, 2024
Evolving Practices in Immune-Related Adverse Event Management: Insights From the IMMUCARE Multidisciplinary BoardRomain Varnier, Clara Fontaine-Delaruelle, Nathalie Freymond, et al.
Cancer Chemotherapy and Pharmacology|April 3, 2023
A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trialAlicja Puszkiel, Benoit You, Léa Payen, et al.
Cancers|April 12, 2022
Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective StudyZoé Guillaume, Emeline Colomba, Jonathan Thouvenin, et al.
Pageof 7